Synergistic Post-Transcriptional Regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 Specific Binding

被引:74
作者
Megiorni, Francesca [1 ]
Cialfi, Samantha [2 ]
Dominici, Carlo [2 ]
Quattrucci, Serena [2 ]
Pizzuti, Antonio [1 ]
机构
[1] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, Dept Pediat & Infantile Neuropsychiat, Rome, Italy
关键词
EPITHELIAL-CELLS; EXPRESSION; MICRORNAS; IDENTIFICATION; MIRNAS; GENE;
D O I
10.1371/journal.pone.0026601
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
microRNAs (miRNAs) are a class of regulatory small non-coding molecules that control gene expression at post-transcriptional level. Deregulation of miRNA functions affects a variety of biological processes also involved in the etiology of several human mendelian and complex diseases. Recently, aberrant miRNA expression has been observed in Cystic Fibrosis (CF), an autosomal-recessive genetic disorder caused by mutations in the CFTR gene, in which a genotype-phenotype correlation is not always found. In order to determine miRNA role in CFTR post-transcriptional regulation, we searched for miR-responsive elements in the CFTR 3'-UTR. In silico analysis, performed using different computational on-line programs, identified some putative miRNAs. Both miR-101 and miR-494 synthetic mimics significantly inhibited the expression of a reporter construct containing the 3'-UTR of CFTR in luciferase assays. Interestingly, miR-101/miR-494 combination was able to markedly suppress CFTR activity by approximately 80% (p<0.001). This is one of the first in vitro studies implicating microRNAs as negative regulators of the CFTR gene expression. miRNA aberrant expression and function might explain the wide phenotypic variability observed among CF patients.
引用
收藏
页数:6
相关论文
共 29 条
[1]
microRNAs in diseases: from candidate to modifier genes [J].
Bandiera, S. ;
Hatem, E. ;
Lyonnet, S. ;
Henrion-Caude, A. .
CLINICAL GENETICS, 2010, 77 (04) :306-313
[2]
MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[3]
MicroRNA profiling of cystic fibrosis intestinal disease in mice [J].
Bazett, Mark ;
Paun, Alexandra ;
Haston, Christina K. .
MOLECULAR GENETICS AND METABOLISM, 2011, 103 (01) :38-43
[4]
Phylogenetic shadowing and computational identification of human microRNA genes [J].
Berezikov, E ;
Guryev, V ;
van de Belt, J ;
Wienholds, E ;
Plasterk, RHA ;
Cuppen, E .
CELL, 2005, 120 (01) :21-24
[5]
The microRNA.org resource: targets and expression [J].
Betel, Doron ;
Wilson, Manda ;
Gabow, Aaron ;
Marks, Debora S. ;
Sander, Chris .
NUCLEIC ACIDS RESEARCH, 2008, 36 :D149-D153
[6]
Elevated miR-155 Promotes Inflammation in Cystic Fibrosis by Driving Hyperexpression of Interleukin-8 [J].
Bhattacharyya, Sharmistha ;
Balakathiresan, Nagaraja S. ;
Dalgard, Clifton ;
Gutti, Usha ;
Armistead, David ;
Jozwik, Cathy ;
Srivastava, Meera ;
Pollard, Harvey B. ;
Biswas, Roopa .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (13) :11604-11615
[7]
miRNAs as serum biomarkers for Duchenne muscular dystrophy [J].
Cacchiarelli, Davide ;
Legnini, Ivano ;
Martone, Julie ;
Cazzella, Valentina ;
D'Amico, Adele ;
Bertini, Enrico ;
Bozzoni, Irene .
EMBO MOLECULAR MEDICINE, 2011, 3 (05) :258-265
[8]
miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy [J].
Cacchiarelli, Davide ;
Incitti, Tania ;
Martone, Julie ;
Cesana, Marcella ;
Cazzella, Valentina ;
Santini, Tiziana ;
Sthandier, Olga ;
Bozzoni, Irene .
EMBO REPORTS, 2011, 12 (02) :136-141
[9]
Update on gene modifiers in cystic fibrosis [J].
Collaco, Joseph M. ;
Cutting, Garry R. .
CURRENT OPINION IN PULMONARY MEDICINE, 2008, 14 (06) :559-566
[10]
Modifier genes in Mendelian disorders: the example of cystic fibrosis [J].
Cutting, Garry R. .
YEAR IN HUMAN AND MEDICAL GENETICS: NEW TRENDS IN MENDELIAN GENETICS, 2010, 1214 :57-69